Jianxin Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianxin Ye has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Guangwei Zhu
Department of Gastrointestinal Surgery 2 Section, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
24 shared publications - Penghang Lin
Department of Gastrointestinal Surgery 2 Section, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
17 shared publications Guangwei Zhu
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Fuzhou City, 350004, Fujian Province, China
15 shared publications- Chunlin Lin
Department of Gastrointestinal Surgery 2 Section, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 1
14 shared publications - Ruofan He
Department of Gastrointestinal Surgery 2 Section, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 1
12 shared publications - Songyi Liu
Department of Gastrointestinal Surgery 2 Section, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 1
12 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-9
Association between technical difficulty and patient prognosis after transanal total mesorectal excision for middle and low rectal cancer: a multicenter cohort study
Background Whether technical difficulty influences outcomes after transanal total mesorectal excision (TaTME) for middle and low rectal cancer remains unclear. This study evaluated the association between technical difficulty and patient outcomes. Methods This multicenter retrospective cohort study included 210 consecutive patients with middle and low rectal cancer who underwent TaTME at three centers in China. A five-item technical difficulty score was constructed using male sex, body mass index ≥ 25 kg/m2, distance from the anal verge ≤5 cm, tumor diameter ≥ 4 cm, and neoadjuvant therapy. Patients were classified into low (0–2 points) and high (3–5 points) technical difficulty groups. Surgical outcomes, recurrence patterns, disease-free survival (DFS), overall survival (OS), and conditional survival were compared. Results Overall, 130 patients were classified into the low technical difficulty group and 80 into the high technical difficulty group. The high technical difficulty group had a longer operative time (249.0 ± 60.0 vs. 220.3 ± 50.1 min, P < 0.001), but major short-term outcomes did not differ significantly. The 3-year DFS and OS rates were 80.2% and 89.0%, respectively. Forty postoperative recurrences were recorded, mainly distant metastases, with most occurring within 2 years. Overall recurrence (17.7% vs. 21.2%, P = 0.588) and local recurrence (3.8% vs. 2.5%, P = 0.711) were comparable between groups. High technical difficulty was not independently associated with DFS (HR 1.06, 95% CI 0.57–2.00, P = 0.849) or OS (HR 1.21, 95% CI 0.52–2.81, P = 0.664). Conclusion Technical difficulty in TaTME was mainly reflected by prolonged operative time and was not significantly associated with increased local recurrence or reduced 3-year DFS/OS. Early surveillance for systemic recurrence remains important. Graphical abstract
- 15 October 2026
- Published by Springer Nature in Surgical Endoscopy
- p. 1-9
Association between technical difficulty and patient prognosis after transanal total mesorectal excision for middle and low rectal cancer: a multicenter cohort study
Background Whether technical difficulty influences outcomes after transanal total mesorectal excision (TaTME) for middle and low rectal cancer remains unclear. This study evaluated the association between technical difficulty and patient outcomes. Methods This multicenter retrospective cohort study included 210 consecutive patients with middle and low rectal cancer who underwent TaTME at three centers in China. A five-item technical difficulty score was constructed using male sex, body mass index ≥ 25 kg/m2, distance from the anal verge ≤5 cm, tumor diameter ≥ 4 cm, and neoadjuvant therapy. Patients were classified into low (0–2 points) and high (3–5 points) technical difficulty groups. Surgical outcomes, recurrence patterns, disease-free survival (DFS), overall survival (OS), and conditional survival were compared. Results Overall, 130 patients were classified into the low technical difficulty group and 80 into the high technical difficulty group. The high technical difficulty group had a longer operative time (249.0 ± 60.0 vs. 220.3 ± 50.1 min, P < 0.001), but major short-term outcomes did not differ significantly. The 3-year DFS and OS rates were 80.2% and 89.0%, respectively. Forty postoperative recurrences were recorded, mainly distant metastases, with most occurring within 2 years. Overall recurrence (17.7% vs. 21.2%, P = 0.588) and local recurrence (3.8% vs. 2.5%, P = 0.711) were comparable between groups. High technical difficulty was not independently associated with DFS (HR 1.06, 95% CI 0.57–2.00, P = 0.849) or OS (HR 1.21, 95% CI 0.52–2.81, P = 0.664). Conclusion Technical difficulty in TaTME was mainly reflected by prolonged operative time and was not significantly associated with increased local recurrence or reduced 3-year DFS/OS. Early surveillance for systemic recurrence remains important. Graphical abstract
- 15 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (45) , 4954-4971
Methylation-driven SOX18 nuclear translocation by IGF2BP1-stabilized METTL21A promotes lymphatic metastasis in gastric cancer
Gastric cancer (GC) is frequently associated with lymph node metastasis, which contributes to a poor prognosis; however, the underlying molecular mechanisms remain incompletely understood. In this study, we identify the N6-methyladenosine (m⁶A) reader IGF2BP1 as a critical driver of lymphatic metastasis in GC. IGF2BP1 is significantly upregulated in GC tissues with lymph node metastasis and is correlated with adverse clinical outcomes. Mechanistically, IGF2BP1 binds to the m⁶A-modified 3′ untranslated region (3′UTR) of METTL21A mRNA, thereby enhancing its mRNA stability and expression levels. METTL21A, a non-histone lysine methyltransferase, interacts with and methylates the transcription factor SOX18, facilitating its nuclear translocation without altering protein stability. Once in the nucleus, SOX18 directly activates the transcription of CXCL12. Secreted CXCL12 promotes lymphangiogenesis and facilitates lymphatic metastasis through CXCR4 signaling. Functionally, both IGF2BP1 and METTL21A enhance tube formation and migration of lymphatic endothelial cells and promote lymphatic metastasis in GC. Notably, METTL21A knockout abolishes IGF2BP1-induced lymphangiogenesis, whereas SOX18 depletion eliminates the pro-lymphangiogenic effects of IGF2BP1. Our findings reveal a previously unrecognized signaling axis—IGF2BP1–METTL21A–SOX18–CXCL12—that links m⁶A-dependent post-transcriptional regulation with methylation-dependent transcriptional activation, offering potential therapeutic targets for the prevention of lymphatic metastasis in gastric cancer.
- 15 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (45) , 4954-4971
Methylation-driven SOX18 nuclear translocation by IGF2BP1-stabilized METTL21A promotes lymphatic metastasis in gastric cancer
Gastric cancer (GC) is frequently associated with lymph node metastasis, which contributes to a poor prognosis; however, the underlying molecular mechanisms remain incompletely understood. In this study, we identify the N6-methyladenosine (m⁶A) reader IGF2BP1 as a critical driver of lymphatic metastasis in GC. IGF2BP1 is significantly upregulated in GC tissues with lymph node metastasis and is correlated with adverse clinical outcomes. Mechanistically, IGF2BP1 binds to the m⁶A-modified 3′ untranslated region (3′UTR) of METTL21A mRNA, thereby enhancing its mRNA stability and expression levels. METTL21A, a non-histone lysine methyltransferase, interacts with and methylates the transcription factor SOX18, facilitating its nuclear translocation without altering protein stability. Once in the nucleus, SOX18 directly activates the transcription of CXCL12. Secreted CXCL12 promotes lymphangiogenesis and facilitates lymphatic metastasis through CXCR4 signaling. Functionally, both IGF2BP1 and METTL21A enhance tube formation and migration of lymphatic endothelial cells and promote lymphatic metastasis in GC. Notably, METTL21A knockout abolishes IGF2BP1-induced lymphangiogenesis, whereas SOX18 depletion eliminates the pro-lymphangiogenic effects of IGF2BP1. Our findings reveal a previously unrecognized signaling axis—IGF2BP1–METTL21A–SOX18–CXCL12—that links m⁶A-dependent post-transcriptional regulation with methylation-dependent transcriptional activation, offering potential therapeutic targets for the prevention of lymphatic metastasis in gastric cancer.
- 5 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (8) , 168347
B3GNT2 promotes gastric cancer metastasis by facilitating membrane trafficking of RYK via N-glycosylation
- 5 July 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1872 (8) , 168347
B3GNT2 promotes gastric cancer metastasis by facilitating membrane trafficking of RYK via N-glycosylation
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1-S17 from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-S17 from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Raw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
Raw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessRaw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
Raw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
Supplementary Materials and Methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
Supplementary Materials and Methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1-S3 from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1-S3 from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Raw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessRaw data from NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression
- Open Access
- 11 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Metrnl ameliorates ulcerative colitis by inhibiting NLRP3 inflammasome activation via ASC
Ulcerative colitis (UC) is characterized by the dysregulation of inflammatory pathways, leading to extensive tissue damage and chronic inflammation. NLRP3 inflammasome promotes inflammatory cytokine maturation and pyroptosis. Meteorin-like protein (Metrnl) has anti-inflammatory effects; however, its specific mechanisms in regulating these pathways remain unclear. This study investigated the effect of Metrnl on UC via regulation of the NLRP3 inflammasome through regulation of its key component, apoptosis-associated speck-like protein containing CARD (ASC). NCM460 and FHC cells were treated with TNF-α to establish a cell validation model. Cells with Metrnl interference or overexpression were intervened with three inflammasome activators (ATP, nigericin, or alum), and a caspase-1 inhibitor (belnacasan). The inflammatory factor levels, ASC mRNA and protein expressions, pyroptosis-related proteins, and inflammasome were detected. Interactions between ASC, Metrnl and inflammasome were determined by protein immunoprecipitation. UC models were constructed using wild-type and Metrnl knockout mice. Histopathological changes and differences in pyroptosis-related protein and inflammasome expressions were examined. Metrnl expression was significantly decreased in colitis, and the inflammatory factors IL-1β and LDH expressions increased at the cellular and animal levels, promoting ASC expression and pyroptosis, and activating the inflammasome. Metrnl interference accelerated inflammation and pyroptosis, which were reversed by Metrnl overexpression. Interactive relationships between Metrnl and ASC were noted. Metrnl may mediate ASC protein expression, and reduce IL-1β expression and pyroptosis in colon epithelial cells through the inhibition of ASC-NLRP3 binding. In vivo studies with DSS-induced colitis models confirmed the significance of these findings. After Metrnl knockout, the colon of normal mice was shorter, and Metrnl-/- UC mice showed more severe colon tissue damage, reduced goblet cells, increased inflammation, and accumulation of pyroptosis protein expression, indicating that Metrnl knockout increases susceptibility to UC. Metrnl interferes with key inflammatory signaling pathways in UC by inhibiting the interaction between ASC and NLRP3, suggesting its potential in UC treatment.
- 11 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessMetrnl ameliorates ulcerative colitis by inhibiting NLRP3 inflammasome activation via ASC
Ulcerative colitis (UC) is characterized by the dysregulation of inflammatory pathways, leading to extensive tissue damage and chronic inflammation. NLRP3 inflammasome promotes inflammatory cytokine maturation and pyroptosis. Meteorin-like protein (Metrnl) has anti-inflammatory effects; however, its specific mechanisms in regulating these pathways remain unclear. This study investigated the effect of Metrnl on UC via regulation of the NLRP3 inflammasome through regulation of its key component, apoptosis-associated speck-like protein containing CARD (ASC). NCM460 and FHC cells were treated with TNF-α to establish a cell validation model. Cells with Metrnl interference or overexpression were intervened with three inflammasome activators (ATP, nigericin, or alum), and a caspase-1 inhibitor (belnacasan). The inflammatory factor levels, ASC mRNA and protein expressions, pyroptosis-related proteins, and inflammasome were detected. Interactions between ASC, Metrnl and inflammasome were determined by protein immunoprecipitation. UC models were constructed using wild-type and Metrnl knockout mice. Histopathological changes and differences in pyroptosis-related protein and inflammasome expressions were examined. Metrnl expression was significantly decreased in colitis, and the inflammatory factors IL-1β and LDH expressions increased at the cellular and animal levels, promoting ASC expression and pyroptosis, and activating the inflammasome. Metrnl interference accelerated inflammation and pyroptosis, which were reversed by Metrnl overexpression. Interactive relationships between Metrnl and ASC were noted. Metrnl may mediate ASC protein expression, and reduce IL-1β expression and pyroptosis in colon epithelial cells through the inhibition of ASC-NLRP3 binding. In vivo studies with DSS-induced colitis models confirmed the significance of these findings. After Metrnl knockout, the colon of normal mice was shorter, and Metrnl-/- UC mice showed more severe colon tissue damage, reduced goblet cells, increased inflammation, and accumulation of pyroptosis protein expression, indicating that Metrnl knockout increases susceptibility to UC. Metrnl interferes with key inflammatory signaling pathways in UC by inhibiting the interaction between ASC and NLRP3, suggesting its potential in UC treatment.
- Open Access
- 4 June 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1)
Development and validation of an interpretable machine learning model for predicting postoperative complications after transanal total mesorectal excision: a multicenter study
This study aimed to develop and externally validate an interpretable machine learning (ML) model for predicting postoperative complications after transanal total mesorectal excision (taTME). We conducted a multicenter case-control study of 245 consecutive patients undergoing taTME at three centers in China. Patients from one center formed the development cohort (n = 185); two independent centers provided an external validation cohort (n = 60). The primary endpoint was any 30-day complication (Clavien-Dindo). Candidate variables were screened with least absolute shrinkage and selection operator (LASSO) and entered into multivariable logistic regression to define features. In total, 11 ML algorithms were trained with tenfold cross-validation; the final model was selected by area under the receiver operating characteristic (ROC) curve (AUC). Discrimination, calibration, decision-curve analysis (DCA), and clinical-impact curves were assessed. Model interpretability was examined with Shapley additive explanations (SHAP). Overall, 27.8% of patients experienced postoperative complications. Six predictors-postoperative C-reactive protein (CRP), preoperative total protein (TP), smoking history, age group (> 80 years), neoadjuvant therapy, and ASA score-were retained. The AdaBoost classifier performed best (development AUC 0.822; 95% CI, 0.751-0.892). External validation demonstrated higher discrimination (AUC 0.872; 95% CI, 0.771-0.972), with accuracy 83.3%, sensitivity 56.25%, and specificity 94.7%. Calibration and DCA supported clinical utility, and clinical-impact curves indicated favorable threshold behavior. The SHAP analysis identified postoperative CRP as the most influential predictor and provided transparent, individualized risk explanations. We developed and externally validated a robust and interpretable ML model to predict complications following taTME. By leveraging routinely available clinical variables and providing transparent predictive explanations, this model can aid clinicians in identifying high-risk patients for targeted interventions, thereby potentially improving perioperative outcomes.
- 4 June 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1)
Open AccessDevelopment and validation of an interpretable machine learning model for predicting postoperative complications after transanal total mesorectal excision: a multicenter study
This study aimed to develop and externally validate an interpretable machine learning (ML) model for predicting postoperative complications after transanal total mesorectal excision (taTME). We conducted a multicenter case-control study of 245 consecutive patients undergoing taTME at three centers in China. Patients from one center formed the development cohort (n = 185); two independent centers provided an external validation cohort (n = 60). The primary endpoint was any 30-day complication (Clavien-Dindo). Candidate variables were screened with least absolute shrinkage and selection operator (LASSO) and entered into multivariable logistic regression to define features. In total, 11 ML algorithms were trained with tenfold cross-validation; the final model was selected by area under the receiver operating characteristic (ROC) curve (AUC). Discrimination, calibration, decision-curve analysis (DCA), and clinical-impact curves were assessed. Model interpretability was examined with Shapley additive explanations (SHAP). Overall, 27.8% of patients experienced postoperative complications. Six predictors-postoperative C-reactive protein (CRP), preoperative total protein (TP), smoking history, age group (> 80 years), neoadjuvant therapy, and ASA score-were retained. The AdaBoost classifier performed best (development AUC 0.822; 95% CI, 0.751-0.892). External validation demonstrated higher discrimination (AUC 0.872; 95% CI, 0.771-0.972), with accuracy 83.3%, sensitivity 56.25%, and specificity 94.7%. Calibration and DCA supported clinical utility, and clinical-impact curves indicated favorable threshold behavior. The SHAP analysis identified postoperative CRP as the most influential predictor and provided transparent, individualized risk explanations. We developed and externally validated a robust and interpretable ML model to predict complications following taTME. By leveraging routinely available clinical variables and providing transparent predictive explanations, this model can aid clinicians in identifying high-risk patients for targeted interventions, thereby potentially improving perioperative outcomes.